Acceder

Bibliografías temáticas / Rabeprazole / Artículos de revistas

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Rabeprazole.

Artículos de revistas sobre el tema "Rabeprazole"

Autor: Grafiati

Publicado: 4 de junio de 2021

Última modificación: 25 de julio de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Rabeprazole".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Cusimano, Joseph. "Rabeprazole." WikiJournal of Medicine 9, no. 1 (2022): 6. http://dx.doi.org/10.15347/wjm/2022.006.

Texto completo

Resumen

Rabeprazole is a proton pump inhibitor that suppresses gastric acid production in the stomach. Available under different brand name products as well as in a variety of combination products, rabeprazole has several medical uses concerning the management of problems of pathological gastric acid. Rabeprazole's adverse effects tend to be mild but can be serious, including deficiencies in essential nutrients, rare incidences of liver damage, and immune-mediated reactions. As a class effect, rabeprazole can increase the risk for osteoporosis, serious infections (including Clostridium difficile infec

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Duan, Zhenya, Yan Wang, Ling Zhang, et al. "An application of continuous flow microreactor in the synthesis and extraction of rabeprazole." International Journal of Chemical Reactor Engineering 19, no. 3 (2021): 287–94. http://dx.doi.org/10.1515/ijcre-2020-0173.

Texto completo

Resumen

Abstract The oxidation of rabeprazole sulfide is a key step in the synthesis of rabeprazole, a drug for the treatment of stomach acid-related disorders. The current rabeprazole production process adopts one pot batch process, which has low reaction efficiency and poor stability. A continuous process can greatly improve the production efficiency and solve the above problems. Therefore, the reaction parameters of rabeprazole in microreactor were explored through laboratory experiments to explore the possibility of continuous production of rabeprazole. Rabeprazole sodium was synthesized by using

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1394 (2012): 35. http://dx.doi.org/10.2165/00128415-201213940-00129.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1159 (2007): 25. http://dx.doi.org/10.2165/00128415-200711590-00075.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1373 (2011): 27. http://dx.doi.org/10.2165/00128415-201113730-00091.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Prakash, Amitabh, and Diana Faulds. "Rabeprazole." Drugs 55, no. 2 (1998): 261–67. http://dx.doi.org/10.2165/00003495-199855020-00009.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Bank, Simmy. "Rabeprazole." Drugs 55, no. 2 (1998): 268. http://dx.doi.org/10.2165/00003495-199855020-00010.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Takeguchi, Noriaki. "Rabeprazole." Drugs 55, no. 2 (1998): 268. http://dx.doi.org/10.2165/00003495-199855020-00011.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Langtry, Heather D., and Anthony Markham. "Rabeprazole." Drugs 58, no. 4 (1999): 725–42. http://dx.doi.org/10.2165/00003495-199958040-00014.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Carswell, Christopher I., and Karen L. Goa. "Rabeprazole." Drugs 61, no. 15 (2001): 2327–56. http://dx.doi.org/10.2165/00003495-200161150-00016.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Baldwin, Claudine M., and Susan J. Keam. "Rabeprazole." Drugs 69, no. 10 (2009): 1373–401. http://dx.doi.org/10.2165/00003495-200969100-00007.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1244 (2009): 38. http://dx.doi.org/10.2165/00128415-200912440-00113.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1256 (2009): 29. http://dx.doi.org/10.2165/00128415-200912560-00090.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1052 (2005): 17. http://dx.doi.org/10.2165/00128415-200510520-00054.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1330 (2010): 31. http://dx.doi.org/10.2165/00128415-201013300-00106.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1342 (2011): 28. http://dx.doi.org/10.2165/00128415-201113420-00100.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1422 (2012): 41–42. http://dx.doi.org/10.2165/00128415-201214220-00139.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1429 (2012): 35. http://dx.doi.org/10.2165/00128415-201214290-00132.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Aman, Kumar Singh*1 Alka Verma2 Ram Sevak Verma3 Ramnivas4 Suraj Mishra5 Pranjul Verma6. "Formulation of Dosage Forms with Rabeprazole: Challenges and Future Perspectives." International Journal in Pharmaceutical Sciences 2, no. 3 (2024): 932–46. https://doi.org/10.5281/zenodo.10868683.

Texto completo

Resumen

Since its introduction in 1999 Rabeprazole is widely used Proton pump inhibitor for the treatment of a number of disease and conditions that are related to the excessive secretion of the gastric acid but still there is a strong need of a dosage form of rabeprazole that meets requirement of all age group of patients. There is a requirement of a stable formulation whose dose can be easily adjusted according to patient. The aim of this review is to describe the discovery and development of Rabeprazole, discuss the issues that arise during formulation of dosage form with rabeprazole and their poss

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Yadav, Shivanee, Harikrishna Yadav, Nidhi Tyagi, and Prashant Kumar Katiyar. "A Review on the Pharmacokinetics and Toxicological Profile of Rabeprazole." International Journal of Pharmaceutical Sciences and Medicine 9, no. 7 (2024): 24–36. http://dx.doi.org/10.47760/ijpsm.2024.v09i07.003.

Texto completo

Resumen

Rabeprazole, a proton pump inhibitor, is used for individuals with ulcers. The prodrug is transformed into an active sulphenamide form by the acidic conditions present in the parietal cells. Rabeprazole inhibits the H+K+ ATPase of the gastric cells, leading to a decrease in the generation of stomach acid in both normal and stimulated situations. The present review was based on the pharmacokinetics and toxicological profile of Rabeprazole. Once absorbed into the body, approximately 96.3–97% of rabeprazole is bound to plasma proteins. In humans, the half-life of rabeprazole is approximately one

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Jia, Rong-Jie, Xiao-Peng Wang, Zhen-Hua Zhang, et al. "Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease." Clinical and Applied Thrombosis/Hemostasis 28 (January 2022): 107602962211307. http://dx.doi.org/10.1177/10760296221130746.

Texto completo

Resumen

To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60 with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following percutaneous coronary intervention (PCI). A total of 360 patients age over 60 undergoing PCI were recruited for antiplatelet therapy involving a combined treatment of aspirin (100 mg/d) and clopidogrel (75 mg/d). The enrolled patients were divided into 4 groups: the control group, the rabeprazole group, the rebamipide group, and the rabeprazole + rebamipide group. The incidence and severity of any upper gastrointest

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Gorakshanath, Ghugarkar Prasad, and Kadam Pallavi Kanifnath. "Design, Development and Physicochemical Evaluation of Formulation for Gastroesophageal Reflux Disease." International Journal of Drug Delivery Technology 15, no. 02 (2025): 01–05. https://doi.org/10.25258/ijddt.15.2.41.

Texto completo

Resumen

The present study mainly involves the targeting the gastro intestinal ulcer by using Rabeprazole formulation. In this main strategy contains the formulation and optimisation of Rabeprazole pellet formulation. The stomach is the primary acidic environment in which nearly all drugs that inhibit proton pumps breakdown. The strategy involve is to coat the Rabeprazole pellet formulation with polymer coat which release the formulation in appropriate site only. Pre formulation date of material detected. Compatibility study of drug with selected excipients was analysed by using Fourier Transform Infra

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Lopina, O. D., B. K. Nurgalieva, and T. L. Lapina. "Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole." Russian Journal of Gastroenterology, Hepatology, Coloproctology 31, no. 4 (2021): 55–63. http://dx.doi.org/10.22416/1382-4376-2021-31-4-55-63.

Texto completo

Resumen

Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatmen

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

&NA;. "Lansoprazole/rabeprazole." Reactions Weekly &NA;, no. 1097-1098 (2006): 18. http://dx.doi.org/10.2165/00128415-200610970-00057.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

&NA;. "Rabeprazole/terbinafine." Reactions Weekly &NA;, no. 864 (2001): 11. http://dx.doi.org/10.2165/00128415-200108640-00029.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

&NA;. "Aciphex (Rabeprazole)." Gastroenterology Nursing 23, no. 2 (2000): 88–89. http://dx.doi.org/10.1097/00001610-200003000-00011.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Khokra, Sukhbir Lal, Balram Choudhary, and Heena Mehta. "RP-HPLC analysis for the simultaneous estimation of rabeprazole sodium and aceclofenac in a combined dosage form." International Current Pharmaceutical Journal 1, no. 12 (2012): 410–13. http://dx.doi.org/10.3329/icpj.v1i12.12450.

Texto completo

Resumen

A rapid, simple and highly sensitive reversed phase high performance liquid chromatographic (RP-HPLC) method has been developed for the quantitative determination of Rabeprazole sodium and Aceclofenac in a combined dosage form. Rabeprazole sodium and Aceclofenac were chromatographed using C-18 column as stationary phase and methanol: acetonitrile: water (60 : 10 : 30 v/v/v) as the mobile phase at a flow rate of 1.0 ml/min at ambient temperature and detected at 280 nm. The retention time (RT) of Rabeprazole sodium and Aceclofenac were found to be 5.611 min and 2.102 minute, respectively. The li

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Jeong, Seung-Hyun, Ji-Hun Jang, and Yong-Bok Lee. "Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling." Biomedicines 11, no. 11 (2023): 3021. http://dx.doi.org/10.3390/biomedicines11113021.

Texto completo

Resumen

Rabeprazole is a proton pump inhibitor that inhibits gastric acid production and increases gastric pH; it is widely used clinically as a treatment option for gastritis and gastric ulcers. However, information on the inter-individual variability of rabeprazole pharmacometrics, which is a key element in establishing its scientific clinical use, is still lacking. Particularly, the differences in pharmacokinetics between genders and the degree of variation in pharmacodynamics have not been clearly identified. Thus, the main purpose of this study was to explore any differences in rabeprazole pharma

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Ashok, Agrawal. "Rabeprazole: The Unique PPIs." Clinical Endocrinology and Metabolism 2, no. 1 (2023): 01–04. https://doi.org/10.31579/2834-8761/014.

Texto completo

Resumen

Rabeprazole is a proton pump inhibitor (PPI). Rabeprazole is a rapid and potent inhibitor of H+, K+-ATPase. Rabeprazole has many advantages over the other currently available proton pump inhibitors in terms of chemical activation rate, onset of action, degree of inhibition of gastric acid secretion, metabolism, and gastric mucus and mucin production. Current review article is undertaken to discuss these unique features.

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Oridate, Nobuhiko, Ryoji Tokashiki, Yusuke Watanabe, Aki Taguchi, Osamu Kawamura, and Kazuma Fujimoto. "Endoscopic Laryngeal Findings in Japanese Patients with Laryngopharyngeal Reflux Symptoms." International Journal of Otolaryngology 2012 (2012): 1–4. http://dx.doi.org/10.1155/2012/908154.

Texto completo

Resumen

Objective. To know the characteristics of endoscopic laryngeal and pharyngeal abnormalities in Japanese patients with laryngopharyngeal reflux symptoms (LPRS).Methods. A total of 146 endoscopic images of the larynx and pharynx (60 pairs for the rabeprazole group and 13 pairs for the control group) were presented to 15 otolaryngologists blinded to patient information and were scored according to several variables potentially associated with laryngopharyngeal reflux. The median value of the 15 scores for each item from each image was obtained. The mean pretreatment scores of each item and total

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Polimeni, Giovanni, Paola Cutroneo, Adele Gallo, Salvatore Gallo, Edoardo Spina, and Achille P. Caputi. "Rabeprazole and Psychiatric Symptoms." Annals of Pharmacotherapy 41, no. 7-8 (2007): 1315–17. http://dx.doi.org/10.1345/aph.1k134.

Texto completo

Resumen

Objective: To report the case of a patient who developed marked anxiety associated with episodes of panic attacks after starting rabeprazole therapy. Case Summary: An otherwise healthy 55-year-old woman was prescribed rabeprazole 20 mg/day administered in the morning tor persistent symptoms of dyspepsia. Ten days later, she presented with a 7 day history of marked anxiety associated with panic attacks, night terror (pavor nocturnus), episodic mental confusion, and attention deficit. Within 2 days of discontinuing rabeprazole, the patient recovered completely from the neuropsychiatric manifesta

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

ZHU, Hai-di, Heng WANG, Xian-ming XIA, Shu-man XU, and Yao LAN. "Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis." Chinese Medical Journal 126, no. 16 (2013): 3146–50. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20130576.

Texto completo

Resumen

Background Several randomized controlled trials (RCTs) have compared endoscopic and symptomatic relapses in patients with erosive gastroesophageal reflux disease (GERD). We have summarized current evidence for rabeprazole 10 or 20 mg once daily for GERD maintenance treatment over 1 or 5 years. Methods MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched, through August 2012, for eligible RCTs of adults with erosive GERD. The efficacies of rabeprazole 10 and 20 mg/d were compared. Results The search identified 288 citations, and five RCTs containing 1480 patient

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Somepalli, Alekhya, Nanda Gopala Krishna Gona, Sri lakshmi Avutu, Naga Sailaja Chandolu, Valli Padma Chilaka, and Sony Priyanka Arava. "A New RP-HPLC Method Development and Validation of Levosulpiride and Rabeprazole." International Journal for Research in Applied Science and Engineering Technology 11, no. 5 (2023): 1590–608. http://dx.doi.org/10.22214/ijraset.2023.51547.

Texto completo

Resumen

Abstract: The Present study was conducted to obtain a new, affordable, cost-effective and convenient method for RP- HPLC determination of Rabeprazole and Levosulpiride in tablet dosage form. The experiment was carried out according to the official specifications of USP–30, ICH- 1996 and Global Quality Guidelines-2002.The method was validated for the parameters like system suitability , selectivity, linearity, accuracy, precision ,LOD, LOQ, and robustness. 20mg Rabeprazole and 75mg Levosulpiride was dissolve in 100 ml of Diluent (1:1,Methanol:Na2HPO4) and was further diluted to get stock soluti

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Trukhan, D. I., E. N. Degovtsov, and A. L. Mazurov. "Choice of protonic pump inhibitor with regard to multimorbidity: a focus on rabeprazol." Medical Council, no. 3 (May 12, 2019): 34–42. http://dx.doi.org/10.21518/2079-701x-2019-3-34-42.

Texto completo

Resumen

Acid-related diseases occupy a leading place in the structure of the incidence of the gastrointestinal tract. One of the important aspects of studying them now is to consider them in combination with coronary heart disease, hypertension, diabetes, asthma and other common diseases and conditions. Proton pump inhibitors are currently the basis for the treatment of acid-related diseases. Although all PPIs are very effective, the antisecretory effects of various drugs of this class may differ in different patients, especially in the presence of comorbidities and comorbidities. The pharmacokinetics

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

Evans, Charity, Gordon Stueck, Sandhya Koobair, Jaimala Maharaj, and Vikesh Maraj. "Patient Acceptance and Economic Outcomes of Rabeprazole Therapy — A Pharmacist-Initiated Interchange Protocol." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 138, no. 5 (2005): 44–49. http://dx.doi.org/10.1177/171516350513800505.

Texto completo

Resumen

Objective: The purpose of this study was to measure the patient acceptance, as well as the individual and provincial cost savings, of switching from other proton pump inhibitor (PPI) therapies to the less costly rabeprazole. Design and setting: This was an uncontrolled, prospective study conducted at a community pharmacy in conjunction with the physicians at the local medical clinic. Patients: Male and female patients over 18 years of age who were currently taking a PPI (omeprazole, lansoprazole, pantoprazole) regularly and who were under the care of a participating physician were eligible. Pa

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Dewan, Bhupesh, and Nisha Philipose. "Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial." Gastroenterology Research and Practice 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/640685.

Texto completo

Resumen

Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial management of uninvestigated dyspepsia.Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a second-generationH2-RA, and rabeprazole and to compare their efficacy.Methods. This was a randomized, open, comparative trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, defined as a score of≥4 on a 7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafut

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

&NA;. "Lansoprazole/omeprazole/rabeprazole." Reactions Weekly &NA;, no. 1161 (2007): 16. http://dx.doi.org/10.2165/00128415-200711610-00051.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

&NA;. "Antirheumatics/bisphosphonates/rabeprazole." Reactions Weekly &NA;, no. 1403 (2012): 8. http://dx.doi.org/10.2165/00128415-201214030-00018.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Hsu, Ping-I., Chien-Lin Chen, Chih-An Shih, et al. "Vonoprazan High-dose Dual, Vonoprazan Triple and Rabeprazole Reverse Hybrid Therapies for First-line Treatment of H. pylori Infection: A Multicenter Randomized Trial." American Journal of Gastroenterology, June 25, 2025. https://doi.org/10.14309/ajg.0000000000003607.

Texto completo

Resumen

OBJECTIVES: The study aimed to compare the efficacy of 14-day vonoprazan high-dose dual, vonoprazan triple and rabeprazaole reverse hybrid therapies for the first-line treatment of H. pylori infection. METHODS: In the multi-center, randomized, open-label trial, we consecutively recruited adult H. pylori-infected patients from six centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day vonoprazan high-dose dual, vonoprazan triple or rabeprazole reverse hybrid therapy. Eradication status was determined by 13C-urea breath test. The primary outcome was the eradication rate of H. pylor

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

"Rabeprazole." Reactions Weekly 1853, no. 1 (2021): 415. http://dx.doi.org/10.1007/s40278-021-95281-y.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

"Rabeprazole." Reactions Weekly 1920, no. 1 (2022): 414. http://dx.doi.org/10.1007/s40278-022-21951-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

"Rabeprazole." Reactions Weekly 1881, no. 1 (2021): 226. http://dx.doi.org/10.1007/s40278-021-05435-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

"Rabeprazole." Reactions Weekly 1876, no. 1 (2021): 289. http://dx.doi.org/10.1007/s40278-021-03538-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

"Rabeprazole." Reactions Weekly 2019, no. 1 (2024): 400. http://dx.doi.org/10.1007/s40278-024-64313-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

"Rabeprazole." Reactions Weekly 1693, no. 1 (2018): 434. http://dx.doi.org/10.1007/s40278-018-43324-z.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

"Rabeprazole." Reactions Weekly 1707, no. 1 (2018): 237. http://dx.doi.org/10.1007/s40278-018-48053-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

"Rabeprazole." Reactions Weekly 1642, no. 1 (2017): 262. http://dx.doi.org/10.1007/s40278-017-27439-x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

"Rabeprazole." Reactions Weekly 1577, no. 1 (2015): 218. http://dx.doi.org/10.1007/s40278-015-10631-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

"Rabeprazole." Reactions Weekly 1656, no. 1 (2017): 393. http://dx.doi.org/10.1007/s40278-017-31721-6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

"Rabeprazole." Reactions Weekly 1526, no. 1 (2014): 116. http://dx.doi.org/10.1007/s40278-014-4763-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!